UNSPSC 51201545: Gusperimus

This classification denotes an immunosuppressant with the molecular formula C17H37N7O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UJ0ZJ76DO9, chemically known as spergualin, 15-deoxy but generally known as gusperimus, which bears US NIH Compound Identifier 55362. European Medicines Agency schedules Gusperimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07991MIG. World Health Organization schedules gusperimus in its Anatomical Therapeutic Chemical (ATC) Classification.

GUSPERIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule gusperimus under HS 29252900 and SITC 51482. As of Q4 2014, GUSPERIMUS remains the US FDA Preferred Term for this commodity. SMILES: OC(NC(=O)CCCCCC/N=C(/N)N)C(=O)NCCCCNCCCN.

UNSPSC 51201545 Gusperimus (Commodity) does not align with the recent state and local opportunities posted under this code. The three most recent postings — Tucson athletic training services for fire and police departments, Tampa medical aid supplies for fire rescue, and Texas HHS pharmacy benefit program information-gathering — span clinical staff services, first-aid consumables, and pharmaceutical supply-chain management, none of which map to the code's stated purpose. The source provides no context defining what "Gusperimus" actually encompasses or why these disparate procurements have been tagged to it, making it impossible to characterize the legitimate scope of work or issuing-body patterns under the code as intended.

The geographic and temporal activity visible in the postings reflects routine municipal and state health-service procurement: the City of Tucson and City of Tampa issued RFP and ITB notices in May and April 2026 respectively, while the Texas Health and Human Services Commission posted an RFI in early April 2026. Without a clear definition of the code's actual commodity or service line and without additional opportunities that clarify the intended scope, this code shows little reliable signal for business development targeting. Any pursuit strategy would require direct clarification from issuing bodies on code application before proposal preparation.